Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort

BACKGROUND: The risk of hepatotoxicity associated with different highly active antiretroviral therapy (HAART) regimens (containing multiple-protease inhibitors, single-protease inhibitors or non nucleoside reverse transcriptase inhibitors) in HIV-HCV co-infected patients has not been fully assessed....

Descripción completa

Detalles Bibliográficos
Autores principales: Torti, Carlo, Lapadula, Giuseppe, Casari, Salvatore, Puoti, Massimo, Nelson, Mark, Quiros-Roldan, Eugenia, Bella, Daniele, Pastore, Giuseppe, Ladisa, Nicoletta, Minoli, Lorenzo, Sotgiu, Giovanni, Mazzotta, Francesco, Caputo, Sergio Lo, Di Perri, Giovanni, Filice, Gaetano, Tinelli, Carmine, Carosi, Giampiero
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1188059/
https://www.ncbi.nlm.nih.gov/pubmed/16018804
http://dx.doi.org/10.1186/1471-2334-5-58

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1188059/
https://www.ncbi.nlm.nih.gov/pubmed/16018804
http://dx.doi.org/10.1186/1471-2334-5-58

Ejemplares similares